Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(100.0%)
2Total
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05069818Unknown

Variance of HRD From Paired Ovarian Cancer

Role: lead

NCT05044091Unknown

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Role: lead

NCT04582552Unknown

The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

Role: lead

NCT04556071Phase 2Unknown

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Role: lead

NCT04566952Phase 2Unknown

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Role: lead

All 5 trials loaded